Have a feature idea you'd love to see implemented?
Let us know!
ADCT Adc Therapeutics SA
Price (delayed)
$1.765
Market cap
$170.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.41
Enterprise value
$19.46M
adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Highlights
The gross profit has contracted by 46% YoY but it has grown by 5% from the previous quarter
The revenue has decreased by 42% YoY but it has increased by 6% from the previous quarter
Adc Therapeutics's equity has decreased by 31% from the previous quarter
The company's net income fell by 18% YoY
Key stats
What are the main financial stats of ADCT
Market
Valuations
Earnings
Shares outstanding
96.69M
Market cap
$170.66M
Enterprise value
$19.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.28
Revenue
$70.72M
Gross profit
$65.89M
Net income
-$212.82M
EBIT
-$120.3M
EBITDA
-$116.81M
Free cash flow
-$142.58M
Per share
Balance sheet
Liquidity
EPS
-$2.41
EPS diluted
-$2.41
Free cash flow per share
-$1.36
Book value per share
-$1.78
Revenue per share
$0.67
TBVPS
$3.33
Total assets
$349.08M
Total liabilities
$521.03M
Debt
$123.07M
Equity
-$171.95M
Working capital
$265.33M
Debt to equity
-0.72
Current ratio
4.92
Quick ratio
4.41
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
-165.2%
Gross margin
93.2%
Net margin
-300.9%
Operating margin
-191.5%
Return on assets
-61.5%
Return on equity
N/A
Return on invested capital
-90.4%
Return on capital employed
-42.8%
Return on sales
-170.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADCT stock price
How has the Adc Therapeutics stock price performed over time
Intraday
0.28%
1 week
-0.84%
1 month
-9.95%
1 year
-7.11%
YTD
-11.31%
QTD
-11.31%
Financial performance
How have Adc Therapeutics's revenue and profit performed over time
Revenue
$70.72M
Gross profit
$65.89M
Operating income
-$135.44M
Net income
-$212.82M
Gross margin
93.2%
Net margin
-300.9%
Adc Therapeutics's net margin has shrunk by 104% YoY but it has increased by 7% QoQ
ADCT's operating margin has dropped by 72% year-on-year but it is up by 6% since the previous quarter
The gross profit has contracted by 46% YoY but it has grown by 5% from the previous quarter
The revenue has decreased by 42% YoY but it has increased by 6% from the previous quarter
Growth
What is Adc Therapeutics's growth rate over time
Valuation
What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.28
Adc Therapeutics's EPS has decreased by 9% YoY but it has increased by 6% QoQ
Adc Therapeutics's equity has decreased by 31% from the previous quarter
The revenue has decreased by 42% YoY but it has increased by 6% from the previous quarter
ADCT's price to sales (P/S) is 36% lower than its last 4 quarters average of 4.1
Efficiency
How efficient is Adc Therapeutics business performance
The ROA has plunged by 64% YoY and by 7% from the previous quarter
Adc Therapeutics's return on sales has decreased by 48% YoY but it has increased by 8% QoQ
The return on invested capital has declined by 23% year-on-year and by 8% since the previous quarter
Dividends
What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADCT.
Financial health
How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 33% less than its total liabilities
Adc Therapeutics's total assets has decreased by 25% YoY and by 6% from the previous quarter
Adc Therapeutics's quick ratio has decreased by 21% from the previous quarter but it has increased by 4% YoY
Adc Therapeutics's debt is 172% higher than its equity
The debt to equity has soared by 68% YoY and by 23% from the previous quarter
Adc Therapeutics's equity has decreased by 31% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.